Construction and validation of a nomogram based on N6‐Methylandenosine‐related lncRNAs for predicting the prognosis of non‐small cell lung cancer patients. (21st June 2022)

• Record Type: Journal Article
• Authors: Xiao, Wenjing; Geng, Wei; Xu, Juanjuan; Huang, Qi; Fan, Jinshuo; Tan, Qi; Yin, Zhengrong; Li, Yumei; Yang, Guanghai; Jin, Yang
• Is Part Of: Cancer medicine. Volume 12:Number 2(2023)
• Page Start: 2058
• Page End: 2074
• Publication Date: 2022-06-21
• Subjects: long non‐coding RNAs -- N6‐methyladenosine -- non‐small cell lung cancer -- prognostic signature; 616.994005
• DOI: 10.1002/cam4.4961
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: The N6‐methyladenosine (m 6 A) can modify long non‐coding RNAs (lncRNAs), thereby influencing a wide array of biological functions. However, the prognosis of m 6 A‐related lncRNAs (m 6 ARLncRNAs) in non‐small cell lung cancer (NSCLC) remains largely unknown. Methods: Pearson correlation analysis was used to identify m 6 ARLncRNAs in 1835 NSCLC patients and with the condition (|Pearson R| > 0.4 and p < 0.001). Univariant Cox regression analysis was conducted to explore the prognostic m 6 ARLncRNAs. We filtered prognostic m 6 ARLncRNAs by LASSO regression and multivariate Cox proportional hazard regression to construct and validate an m 6 ARLncRNAs signature (m 6 ARLncSig). We analyzed the correlation between the m 6 ARLncSig score and clinical features, immune microenvironment, tumor mutation burden, and therapeutic sensitivity and conducted independence and clinical stratification analysis. Finally, we established and validated a nomogram for prognosis prediction in NSCLC patients. Results: Forty‐one m 6 ARLncRNAs were identified as prognostic lncRNAs, and 12 m 6 ARLncRNAs were selected to construct m 6 ARLncSig in the TCGA training dataset. The m 6 ARLncSig was further validated in the testing dataset, GSE31210, GSE37745, GSE30219, and our NSCLC samples. In terms of m 6 ARLncSig, NSCLC patients were divided into high‐ and low‐risk groups, with significantly different overall survival (OS), clinical features (age, sex, and tumor stage), tumor‐infiltrating immune cells, chemotherapeutic sensitivity, radiotherapeutic response, and biological pathways. Moreover, m 6 ARLncSig independently predicted the OS of NSCLC patients. Finally, the robustness and clinical practicability for predicting NSCLC patient prognosis was improved by constructing a nomogram containing the m 6 ARLncSig, age, gender, and tumor stage. Conclusions: Our study demonstrated that m 6 ARLncSig could act as a potential biomarker for evaluating the prognosis and therapeutic efficacy in NSCLC patients. Abstract : The study flow chart and correlation of m 6 ARLncRNAs and m 6 A regulators.